Mochida Pharmaceutical Co., Ltd. (4534) AI Stock Analysis

• Market Cap: ¥100.08B
• Dividend Yield: 2.72%
• Average Volume (3M): 22.91K
• Price to Earnings (P/E): 18.3
• Beta (1Y): 0.58
• Revenue Growth: 5.31%
• EPS Growth: 90.37%
• Country: JP
• Employees: 1,522
• Sector: Healthcare
• Sector Strength: 48
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 2.25
• Shares Outstanding: 36,390,000
• 10 Day Avg. Volume: 18,270
• 30 Day Avg. Volume: 22,906
• PEG Ratio: -0.53
• Price to Book (P/B): 0.98
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 24.19
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: ―

Mochida Pharmaceutical Co., Ltd. demonstrates a strong balance sheet with zero debt and a high equity ratio, which is a significant positive factor for its financial stability. However, the company faces challenges in cash flow management with negative free cash flow impacting its liquidity position. Technical analysis suggests weak market momentum with bearish indicators, and valuation metrics show a fairly priced stock with a reasonable dividend yield. Overall, the stock is in a stable but cautious position, requiring improvements in cash flow and market sentiment to enhance its attractiveness.

Mochida Pharmaceutical Co., Ltd. Business Overview & Revenue Model

Company Description

Mochida Pharmaceutical Co., Ltd. produces and sells pharmaceuticals, skincare products, and diagnostics solutions in Japan. The company provides cardiovascular, analgesic, gastrointestinal, neurological, anti-infective, antidiabetics, and anticancer products, as well as hormone and biological preparations, and biosimilars; diagnostic reagents, such as reagents for fertility/infertility and other reagents; and face and body care, hair care, and skincare products, as well as dermatology, psychiatry, obstetrics, and gynecology products. It also developing drugs for the treatment of intractable diseases. The company has collaboration agreements with Amarin Corporation plc for the development and commercialization of ethyl icosapentate products; and Gene Techno Science Co., Ltd. to develop new regenerative medicine for the treatment of digestive rare and intractable diseases, such as congenital isolated hypoganglionosis. Mochida Pharmaceutical Co., Ltd. was founded in 1913 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Mochida Pharmaceutical Co., Ltd. generates revenue primarily through the sale of its pharmaceutical products. The company's revenue streams include prescription drugs, over-the-counter medications, and medical devices. Mochida invests in research and development to innovate and expand its product offerings, which helps maintain competitive advantage and support revenue growth. Collaborations and partnerships with other pharmaceutical companies and research institutions also contribute to its financial performance by facilitating joint development and commercialization opportunities.

Mochida Pharmaceutical Co., Ltd. Financial Statement Overview

Summary

Mochida Pharmaceutical Co., Ltd. exhibits a stable financial standing with strengths in its balance sheet, characterized by zero debt and a high equity ratio, ensuring financial stability and low risk. The income statement reflects moderate profitability and revenue growth, while the cash flow statement raises concerns with negative free cash flow and undefined cash flow ratios, which could affect liquidity if sustained. Overall, the company is well-positioned but should focus on enhancing cash flow efficiencies.

Income Statement

Mochida Pharmaceutical has shown a resilient performance in its income statement. The TTM gross profit margin stands at 50.44%, indicative of strong cost control. However, the net profit margin of 5.42% highlights some challenges in converting revenue into net income. Revenue growth has been relatively flat with a slight TTM increase of 2.44% from the previous year. The EBIT margin is 6.88%, which is modest, while the EBITDA margin of 3.28% suggests limited operating leverage.

Balance Sheet

The company's balance sheet is robust, with zero total debt and a strong equity base. The debt-to-equity ratio is effectively 0, indicating no reliance on debt. The return on equity (ROE) for the TTM is 4.38%, which is moderate but stable. The equity ratio stands at 78.50%, showcasing a solid asset financing structure with a high proportion of equity.

Cash Flow

Mochida Pharmaceutical's cash flow statement indicates some concerns. While operating cash flow has been positive historically, the TTM data shows zero, which may be due to reporting timing or other factors. The free cash flow for the last annual period was significantly negative due to high capital expenditures. The free cash flow to net income ratio is undefined due to zero free cash flow, posing a risk to cash-based operations.

Breakdown
TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement		Total Revenue
105.40B	105.16B	102.89B	103.26B	110.18B	103.00B
	Gross Profit
53.18B	53.79B	52.07B	55.12B	59.55B	54.79B
	EBIT
7.25B	8.13B	5.80B	8.51B	14.39B	12.00B
	EBITDA
10.56B	11.00B	8.61B	11.71B	17.28B	14.75B
	Net Income Common Stockholders
5.71B	5.68B	4.55B	6.65B	10.57B	8.59B
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
53.58B	51.15B	46.79B	60.51B	61.91B	63.49B
	Total Assets
166.05B	160.12B	158.80B	158.83B	163.14B	161.79B
	Total Debt
0.00	0.00	0.00	190.00M	0.00	0.00
	Net Debt
-45.58B	-45.15B	-33.29B	-46.82B	-48.41B	-54.49B
	Total Liabilities
35.73B	29.43B	30.83B	32.06B	34.50B	34.82B
	Stockholders Equity
130.32B	130.69B	127.97B	126.77B	128.64B	126.97B
Cash Flow		Free Cash Flow
0.00	7.19B	-9.78B	5.13B	4.36B	7.11B
	Operating Cash Flow
0.00	9.35B	-7.48B	7.30B	7.46B	9.20B
	Investing Cash Flow
0.00	17.36B	74.00M	-2.95B	-2.01B	-880.00M
	Financing Cash Flow
0.00	-2.87B	-6.39B	-6.88B	-5.96B	-5.11B

Mochida Pharmaceutical Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2945.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4534, the sentiment is Negative. The current price of 2945 is below the 20-day moving average (MA) of 2961.50, below the 50-day MA of 2997.88, and below the 200-day MA of 3222.76, indicating a bearish trend. The MACD of -17.22 indicates Negative momentum. The RSI at 43.79 is Neutral, neither overbought nor oversold. The STOCH value of 17.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4534.

Mochida Pharmaceutical Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4534	67 Neutral	¥100.08B	18.34	4.35%	2.72%	5.31%	90.37%
Sector *	54 Neutral	$5.25B	3.27	-44.35%	6.27%	16.79%	-0.10%
KKPCF		$960.56M	11.22	9.44%	0.03%	―	―
KSPHF		$1.22B	15.08	5.47%	0.02%	―	―
TWAPF		$1.01B	10.01	11.38%	0.01%	―	―
4886	76 Outperform	¥61.98B	12.94		2.15%	2.06%	-32.48%
4569	73 Outperform	¥78.12B	9.38		0.67%	8.83%	70.61%

Mochida Pharmaceutical Co., Ltd. Corporate Events

Mochida Pharmaceutical Reports Robust Profit Growth for 2024

Mochida Pharmaceutical Co., Ltd. announced its consolidated financial results for the nine months ending December 31, 2024, showing a significant improvement in operating and ordinary profit compared to the previous year. The company reported a 3.2% increase in net sales and marked a substantial rise in profits, indicating a strong performance in its operations despite a drop in comprehensive income.